Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 194

The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.

Prevalence and Clinical Outcomes for Patients With ALK-Positive Resected Stage I to III Adenocarcinoma: Results From the European Thoracic Oncology Platform Lungscape Project

Open access
Blackhall, Fiona H., Peters, Solange, Bubendorf, Lukas, Dafni, Urania, Kerr, Keith M., Hager, Henrik, Soltermann, Alex, O'Byrne, Kenneth J., Dooms, Christoph, Sejda, Aleksandra, Hernández-Losa, Javier, Marchetti, Antonio, Savic, Spasenija, Tan, Qiang, Thunnissen, Erik, Speel, Ernst-Jan M., Cheney, Richard, Nonaka, Daisuke, de Jong, Jeroen, Martorell, Miguel, Letovanec, Igor, Rosell, Rafael, Stahel, Rolf A. · 2014 · Journal of Clinical Oncology

Abstract

Purpose: The prevalence of anaplastic lymphoma kinase (ALK) gene fusion (ALK positivity) in early-stage non–small-cell lung cancer (NSCLC) varies by population examined and detection method used. The Lungscape ALK project was designed to address the prevalence and prognostic impact of ALK positivity in resected lung adenocarcinoma in a primarily European population. Methods: Analysis of ALK status was performed by immunohistochemistry (IHC) and fluorescent in situ hybridization (FISH) in tissue sections of 1,281 patients with adenocarcinoma in the European Thoracic Oncology Platform Lungscape iBiobank. Positive patients were matched with negative patients in a 1:2 ratio, both for IHC and for FISH testing. Testing was performed in 16 participating centers, using the same protocol after passing external quality assessment. Results: Positive ALK IHC staining was present in 80 patients (prevalence of 6.2%; 95% CI, 4.9% to 7.6%). Of these, 28 patients were ALK FISH positive, corresponding to a lower bound for the prevalence of FISH positivity of 2.2%. FISH specificity was 100%, and FISH sensitivity was 35.0% (95% CI, 24.7% to 46.5%), with a sensitivity value of 81.3% (95% CI, 63.6% to 92.8%) for IHC 2+/3+ patients. The hazard of death for FISH-positive patients was lower than for IHC-negative patients (P = .022). Multivariable models, adjusted for patient, tumor, and treatment characteristics, and matched cohort analysis confirmed that ALK FISH positivity is a predictor for better overall survival (OS). Conclusion: In this large cohort of surgically resected lung adenocarcinomas, the prevalence of ALK positivity was 6.2% using IHC and at least 2.2% using FISH. A screening strategy based on IHC or H-score could be envisaged. ALK positivity (by either IHC or FISH) was related to better OS.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1200/jco.2013.54.5921

Cites

4 of 4 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 4 references

Cited by

See all 194

Metadata

Authors
Blackhall, F. H., Peters, S., Bubendorf, L., Dafni, U., Kerr, K. M., Hager, H., Soltermann, A., O'Byrne, K. J., Dooms, C., Sejda, A., Hernández-Losa, J., Marchetti, A., Savic, S., Tan, Q., Thunnissen, E., Speel, E.-J. M., Cheney, R., Nonaka, D., de Jong, J., Martorell, M., Letovanec, I., Rosell, R., & Stahel, R. A.
Venue
Journal of Clinical Oncology
Published
2014-09-01
Volume
32
Issue
25
Pages
2780-2787
ISSN
  • 0732-183X (ISSN-L)
  • 1527-7755
OpenAlex
W1555586856
Cited by
194
References
4
FWCI
20.35
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Prevalence and Clinical Outcomes for Patients With ALK-Positive Resected Stage I to III Adenocarcinoma: Results From the European Thoracic Oncology Platform Lungscape Project. https://app.cochat.ai/papers/10.1200/jco.2013.54.5921
The paper
Blackhall, F. H., Peters, S., Bubendorf, L., Dafni, U., Kerr, K. M., Hager, H., Soltermann, A., O'Byrne, K. J., Dooms, C., Sejda, A., Hernández-Losa, J., Marchetti, A., Savic, S., Tan, Q., Thunnissen, E., Speel, E.-J. M., Cheney, R., Nonaka, D., de Jong, J., . . . Stahel, R. A. (2014). Prevalence and Clinical Outcomes for Patients With ALK-Positive Resected Stage I to III Adenocarcinoma: Results From the European Thoracic Oncology Platform Lungscape Project. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2013.54.5921

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.